We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Collagen Solutions Plc | LSE:COS | London | Ordinary Share | GB00B94T6Y14 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.625 | 6.25 | 7.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
21/7/2016 09:46 | cheers petewy. | 1toad | |
21/7/2016 09:38 | Move up soon imo | babbler | |
21/7/2016 08:15 | Below is quote from Hardman and Co report July 19th Valuation: Our DCF valuation has risen 16% to £54m or 32p per share on the back of these improved results. There are few quoted competitors that could be considered as comparator companies for valuation purposes. The closest, Innocoll, is developing proprietary products and commands an EV of £140m. | petewy | |
20/7/2016 11:56 | babbler- where did you get valuation at 32p from? | 1toad | |
19/7/2016 07:57 | 32p valuation 8.75 p to buy. Even if playing safe and say half that valuation meant around a double bag here. | babbler | |
16/7/2016 10:03 | yes and l noticed that 225k didn't have much effect on the share price | 1toad | |
15/7/2016 18:59 | No, but today's sells took a bit of the cream off the top, even if it was a Friday. Only 12 trades showing L2, inc one delayed ordinary trade, biggy - 225k. f | fillipe | |
13/7/2016 09:50 | fillipe- those sells didn't bring the share price down so that must be a good sign. | 1toad | |
13/7/2016 08:17 | Long term view been in for 2 years.. Patience and steady upwards will be fine for me | jacobjohn7 | |
13/7/2016 08:11 | COS being sold off a bit this morning after the strong rises Needs watching as the rise was on not particularly strong buying, except that of the dirs. f | fillipe | |
12/7/2016 11:57 | Sold some stock to grab some more. | 1toad | |
12/7/2016 10:34 | Movement continues at GWMO £1.1m market cap. Multibagger coming. | apfindley | |
12/7/2016 08:23 | Got a few more .. 19k trade .. Added and shoulda bought two pence cheaper I watch it that much hehe But all good,brill prospects, story on line,easy beatable forecasts, on radar now, and share price not aligned with fickle ftse as much as others . Good luck hold long term then reap the rewards of patience | jacobjohn7 | |
12/7/2016 07:53 | grabbed a few of these. | 1toad | |
11/7/2016 11:05 | COS - being wanted.... and now + 19%. Good to see it lifting out of the post January drop. f | fillipe | |
06/7/2016 07:16 | Any thoughts on results? I'm thinking slightly up from forecast re forecast ... This is time to buy... But got enough of these at higher price doh | jacobjohn7 | |
13/6/2016 07:18 | Collagen Solutions PLC Notice of Results Investor PresentationSource: UK Regulatory (RNS & others)TIDMCOSRNS Number : 9170ACollagen Solutions PLC13 June 2016Collagen Solutions Plc(the "Company" or the "Group")Notice of ResultsInvestor presentationCollagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen-based biomaterials for use in research, diagnostics, medical devices, and regenerative medicine, announces they will issue their preliminary results for the year ending 31 March 2016 on Monday, 11 July 2016.Analyst presentationA briefing for analysts will take place at the offices of Walbrook PR, 4 Lombard Street, London EC3V 9HD at 9.30am on Monday, 11 July 2016.Investor presentationAn afternoon presentation for investors will take place on Tuesday, 12 July in the Black Bar, upstairs at Rocket Bar, 6 Adams Court, Old Broad St, London, EC2N 1DX at 4.30pm for a 4.45pm start.The presentations will be delivered by the new CEO, Jamal Rushdy, who will provide an updated vision and strategic focus for the Company which is reflected in the new website. An updated presentation is also available at If you would like to register to attend either of these events, or require further information, please contact Walbrook PR on 020 7933 8780 or email collagen@walbrookpr. | jacobjohn7 | |
03/5/2016 11:10 | Read Panmure Gordon & Co's note on COLLAGEN SOLUTIONS PLC (COS), out this morning, by visiting hxxps://www.research "Collagen Solutions has announced that CEO Stewart White is to step down with immediate effect, to become Chief Scientific Officer, with the role of Chief Executive to be taken by Mr Jamal Rushdy, currently the group’s Chief Business Officer. Meanwhile the company also announces expected FY16E revenues of £3.2m (PGe £2.8m). All in all, we take today’s news as evidence of positive progress ..." | thomasthetank1 | |
03/5/2016 07:36 | Decent revenue beat ... | 18bt | |
03/5/2016 07:09 | Starting to exceed expectations which ongoing we look to be heading towards the goal of £100m mcap.Be patient get the rewards .. Been in two years now and prepared for the long haul following a world class business | jacobjohn7 | |
03/5/2016 07:07 | Collagen Solutions PLC Leadership changes and preliminary FY revenueSource: UK Regulatory (RNS & others)TIDMCOSRNS Number : 9032WCollagen Solutions PLC03 May 2016Collagen Solutions Plc(the "Company" or the "Group")Announces Leadership Changes and Preliminary FY 2016 RevenueJamal D. Rushdy appointed as Chief Executive OfficerDr. Stewart White moves to the role of Chief Scientific OfficerTrading in the year ending 31 March 2016 exceeds revenue guidanceCollagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen biomaterials for use in research, medical devices, and regenerative medicine, announces the appointment of Jamal D. Rushdy as Chief Executive Officer, and that Dr. Stewart White has transitioned to Chief Scientific Officer (CSO), both with immediate effect. In addition, the Company announces improved year end revenue.Board ChangesMr. Rushdy's initial appointment as Chief Business Officer was announced in November 2015. He has over 20 years' experience in the medical device arena, specifically within two mid-size high growth public companies and three successful start-ups. He has a track record of building businesses with successful exits and transforming organisations through integration and performance improvement, adding value through business development and leadership.Prior to Collagen Solutions, Mr. Rushdy was a Vice President at Tornier Inc, a Minneapolis orthopaedics and biologics company, since 2007, where he served in various leadership roles in U.S. sales operations, global sports medicine and biologics marketing, and business and corporate development. Mr. Rushdy also played a key role in Tornier's successful 2011 Initial Public Offering.As CSO, Dr. White, Collagen Solutions' founder, now leads R&D and corporate development and will focus on the Company's product development and innovation platform whilst also realising value from innovative technologies such as the ChondroMimetic portfolio of assets.Trading updateThe Company also announces preliminary revenue, including other income, of GBP3.2 million for the year ending 31 March 2016, which exceeds prior guidance of GBP2.8 million. These results have been in part driven by the early benefits of the Company's implementation of an improved sales process, together with achievement of global sales and integration synergies. The Company now has dedicated sales people in Europe, Asia, and North America.Commenting on the leadership changes, David Evans, Chairman of Collagen Solutions said, "I would like to thank Stewart for his tireless efforts to develop a strong biomaterials Company. As the CSO, I believe he will bring focus and leadership to our innovation platform."As we look ahead to the need for Collagen Solution's continued growth, we are pleased that Jamal has agreed to take on this additional responsibility. Jamal's experience in global medical technology organisations, and his contribution and recent track record with our Company, gives us confidence that he will continue the momentum and execution of our strategic initiatives."Jamal D. Rushdy commented, "I am excited about the strategy we are pursuing to achieve a leading position in the biomaterials and regenerative medicine market."An announcement further to Jamal D. Rushdy's appointment as Chief Executive Officer containing the disclosures in accordance with the AIM Rules will be made in due course. | jacobjohn7 | |
28/4/2016 09:05 | Thanks for the link, hope this steady newsflow continues. It would be good if we had a timetable from the company of say six months ahead, like a roadmap of the directors plans and for us investors to be able to measure how they are delivering against their plan. Otherwise I for one am reluctant to commit more money at this stage. | nick |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
ADVFN France ADVFN US ADVFN Korea |